Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (ABT) is a global healthcare leader driving innovations in medical devices, diagnostics, nutrition, and branded generics. This page provides investors and industry professionals with timely updates on the company’s latest developments, strategic initiatives, and regulatory milestones.
Access Abbott’s official press releases alongside curated analysis of key events impacting its diversified business segments. Track updates across diabetes care technologies, cardiovascular device approvals, diagnostic system launches, and nutritional product expansions. Our repository ensures you stay informed about earnings announcements, partnership agreements, and clinical trial outcomes without speculative commentary.
Bookmark this page for streamlined access to Abbott’s evolving market position and evidence-based insights into its global healthcare solutions. Check regularly for verified updates that matter to your investment research or industry analysis.
Abbott reported strong financial results for Q3 2021, with sales reaching $10.9 billion, a 23.4% increase year-over-year. GAAP diluted EPS was $1.17, while adjusted diluted EPS grew 42.9% to $1.40. The company projects full-year diluted EPS of $3.55 to $3.65 and adjusted EPS of $5.00 to $5.10, indicating potential 38.4% growth. Significant product launches and acquisitions contributed to this growth, including FDA approvals for new medical devices and an acquisition of Walk Vascular.
On October 18, 2021, Abbott (NYSE: ABT) announced a partnership with Real Madrid to enhance children's health and nutrition worldwide. The initiative will provide nutritional science for the football club's teams and support programs run by the Real Madrid Foundation. Jason Sudeikis, the star of Ted Lasso, participated in an event at the New York Stock Exchange, promoting the partnership alongside teens from the Foundation's Social Sports School. The collaboration aims to impact thousands of children's health and support their potential.
Abbott (NYSE: ABT) has partnered with Real Madrid as its Health Sciences and Nutrition Partner for three years. This collaboration will support education, sports, and social welfare activities for at-risk children in 80 countries, alongside providing nutritional assistance to the men's and women's teams. Abbott aims to tackle malnutrition through this initiative, working with the Real Madrid Foundation to enhance children's health and well-being globally. This partnership aligns with Abbott's goal to improve the lives of over 3 billion people by 2030.
Abbott has established the Abbott Center for Malnutrition Solutions to tackle global malnutrition, focusing on vulnerable groups including mothers, infants, and aging adults. This initiative aligns with Abbott's 2030 Sustainability Plan, aiming to enhance nutrition access for over 3 billion people. Key strategies include expert collaboration, tailored solutions, leveraging scientific innovation, and sustainable practices. Malnutrition is a widespread issue, affecting 1 in 3 people globally, and Abbott plans to use its expertise to make a significant impact.
Abbott (NYSE: ABT) will release its third-quarter 2021 financial results on Wednesday, Oct. 20, 2021, before market opening. Following this, a live webcast of the earnings conference call will occur at 8 a.m. Central time. Interested parties can access it through Abbott's Investor Relations website. Abbott is a global healthcare leader, operating in diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries with a team of 109,000 colleagues.
Abbott (NYSE: ABT) has received FDA approval for its Portico™ with FlexNav™ transcatheter aortic valve replacement (TAVR) system, aimed at treating symptomatic patients suffering from severe aortic stenosis who face high or extreme risks for open-heart surgery. This innovation enhances Abbott's portfolio in structural heart solutions, offering a minimally invasive alternative to traditional surgical valve replacement. The Portico device features a self-expanding TAVR valve designed for optimal blood flow and access to coronary arteries, pushing Abbott's mission of improving patient lives forward.
Abbott (NYSE: ABT) declared a quarterly common dividend of 45 cents per share, marking its 391st consecutive quarterly dividend since 1924. The cash dividend is payable on Nov. 15, 2021, to shareholders of record by Oct. 15, 2021. Abbott has successfully increased its dividend payout for 49 consecutive years and is part of the S&P 500 Dividend Aristocrats Index, highlighting its commitment to returning value to shareholders.
On September 2, 2021, Abbott (NYSE: ABT) announced its acquisition of Walk Vascular, LLC, a company specializing in a minimally invasive thrombectomy system for peripheral blood clots. The acquisition aims to enhance Abbott's endovascular product portfolio, integrating Walk Vascular's innovative JETi Peripheral Thrombectomy Systems. These systems are FDA-cleared and designed to efficiently remove clots while minimizing risks. Financial terms of the deal remain undisclosed.
Abbott (NYSE: ABT) announced results from the Amulet™ LAA Occluder IDE trial, which compares its Amulet device to Boston Scientific's Watchman for treating atrial fibrillation (AFib) patients at stroke risk. The Amulet device demonstrated superior LAA closure (98.9% vs. 96.8%) and was effective in 98.4% of patients. Importantly, patients with Amulet required no blood thinners post-implantation, contrasting with 82% of Watchman patients who needed anticoagulants. The trial supports the recent U.S. approval of Amulet, emphasizing its potential to enhance patient care and reduce stroke risk.
Abbott (NYSE: ABT) has received FDA approval for its Amplatzer™ Amulet™ Left Atrial Appendage Occluder, designed for patients with atrial fibrillation (AFib) at risk of ischemic stroke. This innovative device allows immediate closure of the left atrial appendage, reducing stroke risk and eliminating the need for blood-thinning medication post-procedure. The Amulet features a dual-seal technology, is recapturable, and offers a range of sizes. Previously approved in over 80 countries, this milestone enables U.S. patients and physicians to benefit from this cutting-edge treatment.
FAQ
What is the current stock price of Abbott Labs (ABT)?
What is the market cap of Abbott Labs (ABT)?
